Hamburg Departure Hinged On Filling FDA Leadership Roster
This article was originally published in The Rose Sheet
Susan Mayne brings “new strength and focus to CFSAN” and medical countermeasures expert Luciana Borio moves to chief scientist role. Hamburg offers previews on leadership approaches of Stephen Ostroff and Robert Califf.
You may also be interested in...
Life After White Oak: Hamburg’s Predecessors Offer Glimpse At Where Pharma Might See Her Again
In interviews with “The Pink Sheet,” the last half-dozen FDA commissioners discuss crafting policy on Capitol Hill, building start-up biotechs, consulting and serving on industry boards.
FDA Chief Scientist Ostroff Named Acting Head With Hamburg On Way Out
Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she’ll leave the agency in March with high drug approval numbers and praise from industry groups. Chief Scientist Stephen Ostroff has been named acting head, and some speculate that Robert Califf, newly appointed deputy commissioner for medical products and tobacco, is in line to succeed Hamburg on a permanent basis.
Learning To Drive The ‘Chariot’: FDA Deputy Califf’s New Role
Renowned clinical trialist and cardiologist will become deputy commissioner for medical products and tobacco, a complicated and challenging position.